Novalis Biotechnology Incubation

Modality.ai is an AI-powered platform that detects health conditions using conversational AI. Through dialogue and video, Modality.AI interacts conversationally with the patient to provide health assessment anywhere, anytime. Its system analyzes multimodal data which allows continuous screening and assessing of patients’ health.

Alithea Genomics backgrounds in bioengineering, molecular biology, genomics and lab operations reflect their complementary expertise.

Altavo is a medical device startup focused on creating artificial voice solutions for individuals who have lost their ability to speak due to surgery or disease. By leveraging advanced machine learning and cutting-edge sensor technology, Altavo develops custom, natural-sounding voices that enable voiceless individuals to communicate effectively. The company's innovative approach combines speech recognition and synthesis, significantly enhancing the quality of life for those with speech disorders.

Rarity Bioscience specializes in developing advanced molecular amplification technology for the detection of nucleic acid sequences in biological samples, particularly in liquid biopsies. The company offers an ultrasensitive multiplex assay that enables the identification of rare DNA sequence variants. This innovative platform serves both research and clinical applications, providing physicians with valuable tools for accurate diagnostics and improved patient care.

C-mo is the solution providing a complete assessment of cough, adressing key use-cases across the patient management lifecycle.

Enzyre is a developer of innovative diagnostic technology aimed at enhancing patient care while controlling healthcare costs. The company has created a point-of-care diagnostic device that specializes in blood coagulation testing, capable of measuring up to twelve reactions using a small volume of blood. This technology allows patients to perform tests in various settings, including at home, while traveling, or in critical care environments, eliminating the need for laboratory infrastructure. By bringing laboratory capabilities directly to the patient, Enzyre seeks to improve the quality of life for individuals requiring regular monitoring of their health.

Modality.ai is an AI-powered platform that detects health conditions using conversational AI. Through dialogue and video, Modality.AI interacts conversationally with the patient to provide health assessment anywhere, anytime. Its system analyzes multimodal data which allows continuous screening and assessing of patients’ health.

Carroucell is the microcarrier supplier for cell culture in bioreactor.

Alithea Genomics backgrounds in bioengineering, molecular biology, genomics and lab operations reflect their complementary expertise.

Trince is advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells, both in vitro and ex vivo.

Modality.ai is an AI-powered platform that detects health conditions using conversational AI. Through dialogue and video, Modality.AI interacts conversationally with the patient to provide health assessment anywhere, anytime. Its system analyzes multimodal data which allows continuous screening and assessing of patients’ health.

RheaVita is a pharmaceutical company developing continuous freeze-drying technology for biopharmaceutical products. The company technology integrates all freeze-drying process step unit operations in a continuous production line with the constant infeed of products and the concomitant outfeed of the dried product. Its manufacturing approach avoids scale-up issues, reduces cycle times, allows fast product development, reduces time-to-market, lowers production costs, makes use of smaller manufacturing installations, requires less clean room space, provides improved quality assurance (100% inspection with inherent potential for real-time-release) and leads to improved and uniform product quality and process uniformity.

Grapheal is a Medtech startup focused on developing embedded and wearable biosensors that leverage graphene transistors for enhanced functionality. Their devices are designed to be minimalistic and digital, enabling the dosing of biomarkers and detection of pathogens through a smartphone interface. By integrating advanced sensing nanomaterials with wireless connectivity and data analysis capabilities, Grapheal's biosensors facilitate field diagnostics and remote patient monitoring. This approach aims to make healthcare more accessible and accurate, allowing medical professionals to effectively monitor patient progress and healing.

Enzyre is a developer of innovative diagnostic technology aimed at enhancing patient care while controlling healthcare costs. The company has created a point-of-care diagnostic device that specializes in blood coagulation testing, capable of measuring up to twelve reactions using a small volume of blood. This technology allows patients to perform tests in various settings, including at home, while traveling, or in critical care environments, eliminating the need for laboratory infrastructure. By bringing laboratory capabilities directly to the patient, Enzyre seeks to improve the quality of life for individuals requiring regular monitoring of their health.